特治星(哌拉西林/他佐巴坦)在腹腔内感染中的应用(3)

http://www.100md.com 2003年9月26日 好医生

     7. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996;51(1):99-136

    8. Bryson HM, Brogden RN. Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential . Drugs 1994; 47(3): 506-35

    9. Vogel F, Naber KG, Wacha H, and the Expert Group of the Paul-Ehrlich-Society for Chemotherapy, et al. Pareterale antibiotika bei erwachsenen. Chemotherapie J 1999; 3-49

    10. Johnson CC, Baldessare J, Levinson ME. Peritonitis: update on pathophysiology, clinical manifestations, and management. Clin Infect Dis 1997; 24; 1035-47

    11. Wittmann DH, Schein M, Condon RE. Management of secondary peritonitis. Ann Surg 1996; 222:10-8

    12. Focht J, Nosner K. Empfindlichkeitsspektrum und anderen antibiotika. Krankenhauspharmazic 1997; 11: 531-4

    13. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tzcobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42: 2966-72

    14. Niinikoski J, Tapani H, Alhava E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993; 176;255-61

    15. Eklund AE, Nord CE, Brismar B, et al. A randomized muticenter trial of piperacillin.tazobactam versus imipenem/cilastartin in the treatment of severe intra-abdominal infections. J Anti-microb Chemother 1993; 31 Suppl. A: 79-85

    16. Jhee SS, Gill MA, Yellin AE, et al. Pharmakooekonomische untersuchung zum vergleich von piperacillin/tazobactam und imipenem/cilastatin bei der behandlung von patienten mit intraabdominellen infektionen. Clin Ther 1995; 17: 126-35(李东华)

上一页 第 1 2 3 4 页 下一页

    百拇医药网 http://www.100md.com/html/Dir/2003/09/26/98/940.htm